On January 22, 2020 Genialis and Oncologie reported that they have formed a partnership to evaluate and predict biomarkers for gastric cancer (Press release, Oncologie, JAN 22, 2020, View Source [SID1234553407]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

They initially will concentrate on modeling gene expression signatures that might predict potential treatments for the condition. Houston-based Genialis already has begun applying its Expressions software to the clinical and translational expertise of Oncologie in an effort to improve methodologies for patient stratification, according to the companies.

"One of the most encouraging trends in drug development is innovation around integrating and interrogating diverse datasets," Genialis CEO Rafael Rosengarten said in a statement. "Our work in data science requires a great deal of artistry in addition to technology and benefits from hand-in-hand collaboration with biology domain experts, which makes this opportunity with Oncologie so special.

Boston-based Oncologie said that it eventually wants to take its methodologies to expand into other tumor microenvironment phenotypes.

"To be able to better understand the patient’s tumor microenvironment phenotype and how it is related to patient benefit represents a key objective for the future success of our company," Oncologie CEO Laura Benjamin said in a statement.